Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Clinical Rheumatology|June 8, 2023
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management RegistryRaphael Micheroli, Seraphina Kissling, Kristina Bürki, et al.
Frontiers in Immunology|October 31, 2022
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesCatherine E Raptis, Christoph T Berger, Adrian Ciurea, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Annals of the Rheumatic Diseases|July 28, 2026
Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 yearsWolfgang A Schmidt, Arathi R Setty, Christian Dejaco, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Journal of Leukocyte Biology|August 19, 2016
Antigen-presenting human B cells are expanded in inflammatory conditionsAlexander Shimabukuro-Vornhagen, María García-Márquez, Rieke N Fischer, et al.
The New England Journal of Medicine|October 4, 2023
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid TaperRobert F Spiera, Sebastian Unizony, Kenneth J Warrington, et al.
Annals of the Rheumatic Diseases|February 25, 2015
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusTobias Alexander, Ramona Sarfert, Jens Klotsche, et al.
Pageof 9